P1451 - Long-Term Results of Endoscopic Sleeve Gastroplasty by Obesity Class

Maria Valeria Matteo, MD¹, Vincenzo Bove, MD, PhD¹, Giorgio Carlino, MD¹, Valerio Pontecorvi, MD, PhD¹, Martina De Siena, MD¹, Loredana Gualtieri, MD¹, Chiara Massari, ¹, Nausicaa Antonini, ¹, Chiara Chiarini, ¹, Michaela Angeletti, ¹, Cristiano Spada, MD, PhD¹, Ivo Boskoski, MD^2
1Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Lazio, Italy; ²Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Lazio, Italy

Introduction: Obesity is a chronic and recurrent disease. In the past few years, Endoscopic sleeve gastroplasty (ESG) has emerged as a minimally invasive technique to fill the therapeutic gap between medical and surgical approaches to obesity. Most of the published data on ESG show the results of the procedure in the first 12-24 months. In this study, we aim to report long-term results for all class obesity of ESG to further implement the evidence of long-term effectiveness.

Methods: A retrospective analysis was performed on a prospective database including patients with obesity (BMI ≥ 30 kg/m²) who underwent ESG between May 2017 and May 2021 at a single tertiary Center. Weight loss outcomes (%EWL, %TBWL) were evaluated during follow-up and stratified according to obesity class. All patients were included in a multidisciplinary follow-up scheduled at 1, 3, 6, and then every 6 months.

Results: Between May 2017 and May 2021, 252 subjects (73% Female) underwent ESG with a median BMI of 37.2 (35.3-40.8) kg/m² at baseline and a median age of 45 (36-54) years. No severe procedure-related adverse events occurred. Of 252 subjects, 58 (23%) had obesity class I (BMI 30-34.9), 120 (48%) had obesity class II (BMI 35-39.9), and 74 (29%) had class III obesity (BMI ≥ 40). Overall, 58% (44/76) of patients showed an %EWL >25% at 30-36 months of follow-up, respectively, the current threshold defining the efficacy of a primary bariatric endoscopic procedure. Similarly, 71% (54/76) of subjects showed a %TBWL > 5% two years after ESG, which is relevant as this threshold is related to obesity-related comorbidities improvement. Weight loss results according to BMI class are reported in Table 1.

Discussion: Our experience confirms that ESG in the setting of a multidisciplinary approach is a safe and effective procedure for the treatment of obesity, associated with sustained weight loss in all obesity classes.


Disclosures:


Maria Valeria Matteo, MD¹, Vincenzo Bove, MD, PhD¹, Giorgio Carlino, MD¹, Valerio Pontecorvi, MD, PhD¹, Martina De Siena, MD¹, Loredana Gualtieri, MD¹, Chiara Massari, ¹, Nausicaa Antonini, ¹, Chiara Chiarini, ¹, Michaela Angeletti, ¹, Cristiano Spada, MD, PhD¹, Ivo Boskoski, MD². P1451 - Long-Term Results of Endoscopic Sleeve Gastroplasty by Obesity Class, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.